Spots Global Cancer Trial Database for acute lymphoblastic leukemia (all)
Every month we try and update this database with for acute lymphoblastic leukemia (all) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | NCT02212561 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Mixed Phenotype... | Selinexor Fludarabine Cytarabine methotrexate/hy... | - 24 Years | St. Jude Children's Research Hospital | |
| A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL | NCT02046694 | Acute Lymphobla... | Allopurinol | - 30 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | NCT02646839 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | CliniMacs TCR a... | - 21 Years | Children's Hospital Los Angeles | |
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | NCT01816230 | Hematological M... Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | NiCord® | 12 Years - 65 Years | Gamida Cell ltd | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | NCT04029688 | Acute Myeloid L... Acute Lymphobla... Neuroblastoma Solid Tumors | Idasanutlin Venetoclax Cyclophosphamid... Topotecan Fludarabine Cytarabine Intrathecal Che... | 0 Years - 30 Years | Hoffmann-La Roche | |
| Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study | NCT02894645 | Acute Lymphobla... | Prednisolone Dexamethasone L-Asparaginase Vincristine Methotrexate Daunorubicin Doxorubicin Cyclophosphamid... Cytarabine 6-Mercaptopurin... Thioguanine Fludarabine Imatinib | 1 Year - 17 Years | National University Hospital, Singapore | |
| Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | NCT01050764 | Leukemia, Acute Chronic Myeloge... Myelodysplastic... Non-Hodgkin Lym... Chronic Lymphoc... Acute Myelogeno... Acute Lymphobla... | Regulatory T-ce... Conventional T-... Melphalan Thiotepa Fludarabine Anti-thymocyte ... CliniMACS CD34 ... | - 60 Years | Stanford University | |
| Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies | NCT01221857 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Non-Hodgkin's L... Hodgkin's Disea... | NiCord® | 8 Years - 65 Years | Gamida Cell ltd | |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| CTL019 Out of Specification MAP for ALL or DLBCL Patients | NCT03601442 | Acute Lymphobla... Diffuse Large B... | CTL019 | 1 Day - 25 Years | Novartis | |
| CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) | NCT05349201 | Diffuse Large B... Acute Lymphobla... | KYMRIAH YESCARTA | 18 Years - 30 Years | Novartis | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota | |
| Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell | NCT01660607 | Myeloid Leukemi... Acute Myelogeno... Myelodysplastic... Lymphoma, Non-H... Acute Lymphobla... Myeloproliferat... Acute Myeloid L... Acute Leukemia Chronic Myeloge... | Conventional T ... | 13 Years - 60 Years | Stanford University | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | NCT02200380 | For Donors Related Donors ... For Recipients Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Non-Hodgkins Ly... Hodgkins Diseas... Chronic Lymphoc... | CDX-301 CDX-301 and ple... | 18 Years - 70 Years | Celldex Therapeutics | |
| Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study | NCT03260101 | Acute Myelogeno... Acute Lymphobla... Non Hodgkin Lym... Hodgkin Lymphom... | non intervation... | 18 Years - 70 Years | Cellect Biotechnology | |
| A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL | NCT01439347 | Acute Lymphobla... | Vincristine Sul... Vincristine Sul... | 60 Years - | Spectrum Pharmaceuticals, Inc | |
| Bio-CAR-T BS Study | NCT05366569 | Diffuse Large B... Primary Mediast... Acute Lymphobla... | 18 Years - 70 Years | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | ||
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | NCT00145613 | Acute Lymphobla... Acute Myeloid L... Secondary AML Myelodysplastic... Secondary MDS Chronic Myeloid... Juvenile Myelom... Paroxysmal Noct... Lymphoma, Non-H... Hodgkin Disease | Stem Cell Trans... Miltenyi Biotec... Systemic chemot... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) | NCT00179764 | Tumors Malignant Melan... Hematological M... Myelogenous Leu... Leukemia, Lymph... | Immunoablative ... Busulfan pharma... Central Nervous... | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | NCT01816230 | Hematological M... Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | NiCord® | 12 Years - 65 Years | Gamida Cell ltd | |
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Bio-CAR-T BS Study | NCT05366569 | Diffuse Large B... Primary Mediast... Acute Lymphobla... | 18 Years - 70 Years | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | ||
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | NCT01816230 | Hematological M... Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | NiCord® | 12 Years - 65 Years | Gamida Cell ltd | |
| Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | NCT01527838 | Non-Hodgkin's L... Hodgkin's Disea... Chronic Lymphoc... Acute Myelogeno... Acute Lymphobla... | Single FT1050 t... | 18 Years - 65 Years | Fate Therapeutics | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | NCT00001748 | Graft vs Host D... Hematologic Neo... Lymphoma Myelodysplastic... Myeloid Leukemi... | Peripheral bloo... | - | National Institutes of Health Clinical Center (CC) | |
| Bio-CAR-T BS Study | NCT05366569 | Diffuse Large B... Primary Mediast... Acute Lymphobla... | 18 Years - 70 Years | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | ||
| Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | NCT02226861 | Acute Lymphobla... Acute Myelogeno... Chronic Lymphoc... Chronic Myeloge... MDS | CliniMACS CD34 ... ULD IL-2 | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | NCT02646839 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | CliniMacs TCR a... | - 21 Years | Children's Hospital Los Angeles | |
| CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) | NCT05349201 | Diffuse Large B... Acute Lymphobla... | KYMRIAH YESCARTA | 18 Years - 30 Years | Novartis | |
| Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | NCT02226861 | Acute Lymphobla... Acute Myelogeno... Chronic Lymphoc... Chronic Myeloge... MDS | CliniMACS CD34 ... ULD IL-2 | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia | NCT05168748 | Acute Lymphobla... | IMJ995 single a... | 1 Year - | Novartis | |
| Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older | NCT02647190 | Acute Lymphobla... Newly Diagnosed... Aged 60 Years o... | Erwinia Chrysan... | 60 Years - | Memorial Sloan Kettering Cancer Center | |
| IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | NCT01885897 | Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Lymphoma Myeloma Chronic Lymphoc... Chronic Myeloge... | ALT-803 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | NCT00145613 | Acute Lymphobla... Acute Myeloid L... Secondary AML Myelodysplastic... Secondary MDS Chronic Myeloid... Juvenile Myelom... Paroxysmal Noct... Lymphoma, Non-H... Hodgkin Disease | Stem Cell Trans... Miltenyi Biotec... Systemic chemot... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Cord Blood Transplant in Adults With Blood Cancers | NCT05884333 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... Myeloproliferat... Non-Hodgkin's L... | Conditioning Ch... Cord blood graf... | 21 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| International Study for Treatment of High Risk Childhood Relapsed ALL 2010 | NCT03590171 | Acute Lymphobla... | Bortezomib | - 17 Years | Charite University, Berlin, Germany | |
| A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma | NCT03181126 | Acute Lymphobla... Lymphoblastic L... | Navitoclax Chemotherapy Venetoclax | 4 Years - | AbbVie | |
| International Study for Treatment of High Risk Childhood Relapsed ALL 2010 | NCT03590171 | Acute Lymphobla... | Bortezomib | - 17 Years | Charite University, Berlin, Germany | |
| Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies | NCT01221857 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Non-Hodgkin's L... Hodgkin's Disea... | NiCord® | 8 Years - 65 Years | Gamida Cell ltd | |
| Genetic Study of Familial Acute Lymphoblastic Leukemia | NCT03067584 | Acute Lymphobla... | - | St. Jude Children's Research Hospital | ||
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota | |
| A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | NCT03236857 | Malignancies Acute Lymphobla... Acute Myeloid L... Non-Hodgkin's L... Neuroblastoma | chemotherapy venetoclax | 0 Years - 25 Years | AbbVie | |
| Expanded Access to Venetoclax | NCT03123029 | Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... Non-Hodgkin's L... Acute Lymphobla... Amyloidosis Plasma Cell Leu... | Venetoclax | - | AbbVie | |
| Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy | NCT00433745 | Myelodysplastic... Acute Myeloid L... Chronic Myeloid... | WT1 Peptide Vac... | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) | NCT05291390 | Acute Myeloid L... Acute Lymphobla... | Pyronaridine Te... | 18 Years - | Armaceutica, Inc. | |
| An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | NCT03844048 | Chronic Lymphoc... Acute Myeloid L... Multiple Myelom... Non-Hodgkin's L... Acute Lymphobla... Cancer | Venetoclax | - | AbbVie | |
| Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | NCT02212561 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Mixed Phenotype... | Selinexor Fludarabine Cytarabine methotrexate/hy... | - 24 Years | St. Jude Children's Research Hospital | |
| CTL019 Out of Specification MAP for ALL or DLBCL Patients | NCT03601442 | Acute Lymphobla... Diffuse Large B... | CTL019 | 1 Day - 25 Years | Novartis | |
| Cord Blood Transplant in Adults With Blood Cancers | NCT05884333 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... Myeloproliferat... Non-Hodgkin's L... | Conditioning Ch... Cord blood graf... | 21 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Expanded Access to Venetoclax | NCT03123029 | Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... Non-Hodgkin's L... Acute Lymphobla... Amyloidosis Plasma Cell Leu... | Venetoclax | - | AbbVie | |
| Reduce Sedentary Time (ReSeT) in Acute Lymphoblastic Leukemia (ALL) | NCT06182163 | Acute Lymphobla... | Sedentary time ... | 12 Years - 18 Years | Children's Hospital Los Angeles | |
| CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | NCT02061800 | Chronic Myeloid... Acute Myelogeno... Myelodysplastic... Juvenile Myelom... Acute Lymphobla... Lymphoma (Hodgk... | CliniMACS CD34+... Thiotepa Cyclophosphamid... Alemtuzumab Tacrolimus Melphalan Busulfan Fludarabine Methylprednisol... | - 22 Years | Columbia University | |
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia | NCT00001623 | Graft vs Host D... Hematologic Neo... Leukemia Multiple Myelom... Myelodysplastic... | Allogeneic Bone... | 10 Years - 55 Years | National Institutes of Health Clinical Center (CC) | |
| CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) | NCT05349201 | Diffuse Large B... Acute Lymphobla... | KYMRIAH YESCARTA | 18 Years - 30 Years | Novartis | |
| Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) | NCT05291390 | Acute Myeloid L... Acute Lymphobla... | Pyronaridine Te... | 18 Years - | Armaceutica, Inc. | |
| Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older | NCT02647190 | Acute Lymphobla... Newly Diagnosed... Aged 60 Years o... | Erwinia Chrysan... | 60 Years - | Memorial Sloan Kettering Cancer Center | |
| Bright Ideas - CIN Feasibility Study | NCT04929899 | Acute Lymphobla... | Bright Ideas - ... | 4 Years - 18 Years | The Hospital for Sick Children | |
| A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | NCT02200380 | For Donors Related Donors ... For Recipients Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Non-Hodgkins Ly... Hodgkins Diseas... Chronic Lymphoc... | CDX-301 CDX-301 and ple... | 18 Years - 70 Years | Celldex Therapeutics | |
| Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study | NCT03260101 | Acute Myelogeno... Acute Lymphobla... Non Hodgkin Lym... Hodgkin Lymphom... | non intervation... | 18 Years - 70 Years | Cellect Biotechnology | |
| Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation | NCT02259348 | Acute Lymphobla... Acute Myeloid L... Myeloid Sarcoma Chronic Myeloge... Juvenile Myelom... Myelodysplastic... Non-Hodgkin Lym... | Cyclophosphamid... Fludarabine G-CSF Interleukin-2 Melphalan Thiotepa Rituximab Natural killer ... T-cell depleted... CD45RA-depleted... | - 21 Years | St. Jude Children's Research Hospital | |
| Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study | NCT03260101 | Acute Myelogeno... Acute Lymphobla... Non Hodgkin Lym... Hodgkin Lymphom... | non intervation... | 18 Years - 70 Years | Cellect Biotechnology | |
| Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | NCT02790515 | Acute Lymphobla... Acute Myeloid L... Myeloid Sarcoma Chronic Myeloid... Juvenile Myelom... Myelodysplastic... Non-Hodgkin Lym... | Anti-thymocyte ... Blinatumomab Cyclophosphamid... Fludarabine G-CSF Melphalan Mesna Rituximab Tacrolimus Thiotepa HPC,A Infusion CliniMACS Sirolimus | - 21 Years | St. Jude Children's Research Hospital | |
| Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS | NCT02730299 | Hematological M... Acute Lymphobla... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Lymphoma Acute Leukemia | NiCord® (omidub... Cord Blood Unit | 12 Years - 65 Years | Gamida Cell ltd | |
| A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation | NCT00672152 | Acute Myelogeno... Chronic Myeloge... Acute Lymphobla... Myelodysplastic... B Cell Malignan... | WT1 derived pep... | 18 Years - | Duke University | |
| Safety and Efficacy Evaluation of CD19-UCART | NCT03229876 | Acute Lymphobla... Non Hodgkin Lym... | CD19-UCART | 1 Year - 65 Years | Bioray Laboratories | |
| PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia | NCT00944008 | Acute Lymphobla... | DepoCyte | 16 Years - 30 Years | PETHEMA Foundation | |
| Reduce Sedentary Time (ReSeT) in Acute Lymphoblastic Leukemia (ALL) | NCT06182163 | Acute Lymphobla... | Sedentary time ... | 12 Years - 18 Years | Children's Hospital Los Angeles | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
